PCAR vs RNA · P/E 25, rev $33.66B vs rev $22.6M
PACCAR Inc (PCAR) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
PACCAR Inc (PCAR) is a farm & heavy construction machinery company listed on NASDAQ.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported PCAR revenue for 2024-12-31 was $33.66B. Net income was $4.16B. Revenue was down 4.2% from 2023-12-31 to 2024-12-31. PCAR currently screens at market cap $61.75B and trailing P/E 25.0.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
PCAR currently screens at market cap $61.75B and trailing P/E 25.0. RNA currently screens at market cap $217.5M.
Not investment advice. Open the PCAR and RNA stock pages for the full models.
Not investment advice.